Phenotype-directed analysis of genotype in early-onset, familial breast cancers

Pathology

Volumn 38, Issue 6, 2006, Pages 520-527

  Price, Gareth R ^a,b   Armes, Jane E ^b,c,d   Ramus, Susan J ^b   Provenzano, Elena ^b   Kumar, Beena ^b   Cowie, Tiffany F ^c   Ciciulla, John ^a   Hutchins, Anne Marie ^b   Thomas, Mervyn ^e   Venter, Deon J ^a,c,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b Victorian Breast Cancer Research Consortium   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MATER HOSPITAL   (Australia)

^e Emphron Informatics Pty Ltd   (Australia)

Author keywords

BRCA1; BRCA2; Breast cancer; CDC34; Comparative genomic hybridisation; Early onset; Familial breast cancer

Indexed keywords

BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ANAPHASE PROMOTING COMPLEX; ANAPHASE-PROMOTING COMPLEX; DNA; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CHROMOSOME MAP; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FAMILIAL CANCER; FEMALE; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; METASTASIS; MORPHOLOGY; ONCOGENE; ONCOGENE CDC34; PROGNOSIS; STRATIFICATION; TELOMERE; BREAST TUMOR; CLUSTER ANALYSIS; GENETICS; GENOTYPE; MITOSIS; NUCLEIC ACID HYBRIDIZATION; ONSET AGE; PATHOLOGY; PHENOTYPE;

ADULT; AGE OF ONSET; BRCA1 PROTEIN; BREAST NEOPLASMS; CLUSTER ANALYSIS; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; MITOSIS; NUCLEIC ACID HYBRIDIZATION; PHENOTYPE; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 34247131811     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020601024052     Document Type: Article

References (19)

1. Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998; 83: 2335-45.
2. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999; 59: 2011-7.
3. Provenzano E, Hopper JL, Giles GG, et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003; 39: 622-30.
4. Taucher S, Rudas M, Mader RM, et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer 2003; 98: 2547-53.
5. Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999; 8: 741-7.
6. Southey MC, Tesoriero AA, Andersen CR, et al. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer 1999; 79: 34-9.
7. Tesoriero A, Andersen C, Southey M, et al. De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 1999; 65: 567-9.
8. Ramus SJ, Pharoah PD, Harrington P, et al. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 2003; 63: 417-23.
9. Venter DJ, Ramus SJ, Hammet FM, et al. Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines. Cancer Genet Cytogenet 2005; 160: 134-40.
10. Jonsson G, Naylor TL, Vallon-Christersson J, et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005; 65: 7612-21.
11. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997; 57: 1222-7.
12. Wessels LF, van Welsem T, Hart AA, et al. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002; 62: 7110-7.
13. Kleivi K, Diep CB, Pandis N, et al. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas. J Pathol 2005; 207: 14-9.
14. Wang ZC, Lin M, Wei LJ, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004; 64: 64-71.
15. Armes JE, Hammet F, de Silva M, et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 2004; 23: 5697-702.
16. Butz N, Ruetz S, Natt F, et al. The human ubiquitin-conjugating enzyme Cdc34 controls cellular proliferation through regulation of p27Kip1 protein levels. Exp Cell Res 2005; 303: 482-93.
17. Tigli H, Buyru N, Dalay N. Molecular analysis of the p27/kip1 gene in breast cancer. Mol Diagn 2005; 9: 17-21.
18. Reimers N, Zafrakas K, Assmann V, et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004; 10: 3422-8.
19. Tang Y, Kesavan P, Nakada MT, et al. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2004; 2: 73-80.